SELLAS Life Sciences Q3 net loss widens on higher R&D costs
SLS•SELLAS Life Sciences’ third-quarter net loss widened year over year to $10.09 million as research and development and administrative expenses rose. The company ended the quarter with $134.7 million in cash and expects topline primary endpoint results from its Phase 3 REGAL trial this month.
1. Quarterly results and outlook
SELLAS reported a third-quarter net loss of $10.09 million, or $0.05 per basic share, and operating expenses of $11.31 million. Higher research and development costs reflected increased manufacturing, clinical trial and regulatory expenses for pipeline programs; general and administrative expenses rose on higher non-cash stock-based compensation and professional fees. The company ended the quarter with $134.7 million in cash and expects topline primary endpoint results from its Phase 3 REGAL trial this month. Preliminary topline data from its Phase 2 SLS009 trial in newly diagnosed AML is expected in the fourth quarter of 2026.
